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Abstract 
Increased expression of specific calcium channels in some cancers and the role of calcium 
signaling in proliferation and invasion have led to studies assessing calcium channel 
inhibitors as potential therapies for some cancers. The use of channel activators to promote 
death of cancer cells has been suggested, but the risk of activators promoting cancer cell 
proliferation and the importance of the degree of channel over-expression is unclear. We 
developed an MCF-7 breast cancer cell line with inducible TRPV1 overexpression and 
assessed the role of TRPV1 levels on cell death mediated by the TRPV1 activator capsaicin 
and the potential for submaximal activation to promote proliferation. The TRPV1 level was a 
determinant of cell death induced by capsaicin. A concentration response curve with varying 
TRPV1 expression levels identified the minimum level of TRPV1 required for capsaicin 
induced cell death. At no level of TRPV1 over-expression or capsaicin concentration did 
TRPV1 activation enhance proliferation. Cell death induced by capsaicin was necrotic and 
associated with up-regulation of c-Fos and RIP3. These studies suggest that activators of 
specific calcium channels may be an effective way to induce necrosis and that this approach 
may not always be associated with enhancement of cancer cell proliferation. 
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1. Introduction
Calcium is an important regulator of a variety of cellular processes many of which are de-
regulated in cancer cells, such as proliferation, migration and cell death [1, 2]. Increases in 
the expression of specific calcium permeable ion channels occur in a variety of cancer types 
[1]. These include increased levels of TRPM8 [3, 4], TRPV6 [5, 6] and TRPV2 [7] in some 
prostate cancers and increased TRPC3 and TRPC6 in ovarian cancer [8, 9]. In some cases, 
alterations in the expression of specific calcium permeable ion channels occur predominantly 
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in specific cancer subtypes. Examples of this are seen in breast cancers, where increases in 
the levels of the highly selective calcium channel TRPV6 [10] are associated with the poor 
prognosis basal subtype [11].  
 
Numerous studies have now also identified that silencing and/or pharmacological inhibition 
of overexpressed calcium ion channels in cancer cells may attenuate key aspects of cancer 
progression, including proliferation and metastasis. Inhibitory RNA-mediated silencing of 
TRPC3 reduces the proliferation of the SKOV3 ovarian cancer cell line [8] and silencing or 
pharmacological inhibition of ORAI1 reduces metastasis of MDA-MB-231 breast cancer 
cells in vivo [12]. These and other studies [13-15] have provided compelling evidence that 
overexpression of a calcium permeable ion channel can promote key hallmarks of cancer [16] 
and that inhibition of calcium permeable ion channels overexpressed in specific cancers may 
provide a strategy for cancer therapy. An alternative approach that has been proposed (but 
less studied) is the activation of an overexpressed calcium permeable ion channels to induce 
cancer cell death [1, 17]. 
 
Calcium is a critical regulator of cell death, with sustained and high (> 1 M) increases in 
intracellular free Ca
2+
 ([Ca
2+
]i) associated with the induction of apoptotic or necrotic cell 
death [18]. The critical importance of elevated levels of [Ca
2+
]i in cell death pathways has 
been widely studied in neurons and cardiac cells [19]. In neurons, cell death due to Ca
2+
 
overload is often associated with the cleavage and in some cases inactivation of calcium 
efflux transporters located on the plasma membrane, [20, 21]. The consequences of this 
attenuation of Ca
2+
 efflux mechanisms is augmentation of elevations in [Ca
2+
]i and promotion 
of cell death pathways modulated by Ca
2+
, such as those of the mitochondria [22].  
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In prostate cancer cells, Zhang and Barritt [17] demonstrated that silencing TRPM8 reduces 
cell viability and induces apoptosis in LNCaP cells, and that activation of TRPM8 with the 
non-selective TRPM8 activator menthol [23] also reduces cell viability and induces apoptosis 
[17]. Menthol also induces cell death, but not apoptosis, in a bladder cancer cell line with 
elevated levels of TRPM8 [24]. Transient expression of the drosophila TRPL (constitutively 
active) in the LNCaP cells reduces cell viability and increases apoptosis [25]. Activation of 
overexpressed TRPV2 in a bladder cancer cell line with cannabidiol and activation of 
overexpressed TRPV1 with capsaicin in a lung cancer cell line both cause apoptosis [26, 27]. 
One potential limitation of activating an overexpressed calcium permeable ion channel as a 
therapeutic approach for cancer therapy is the possibility of the activator producing levels of 
Ca
2+
 influx that are not sufficient to induce cell death, but which activate calcium sensitive
cell cycle pathways [28] and thus promote proliferation. It is also still unclear how the level 
of calcium channel overexpression may influence the sensitivity of cancer cells to cell death 
via channel activation. In these studies we explored these issues using MCF-7 breast cancer 
cells with inducible TRPV1 over-expression. TRPV1 is a calcium permeable ion channel 
expressed in sensory neurons [29], keratinocytes [30] and lung cells [26], with a role in the 
sensing of elevated temperatures, thermal pain [31] and regulating inflammation and 
neurogenesis [32]. TRPV1 is activated by the hot component of chili peppers capsaicin and is 
sensitive to a variety of pharmacological activators and inhibitors, which have often been 
developed as part of the search for novel therapies for pain [33] and overactive bladder [34]. 
Elevated TRPV1 expression occurs in colon [35], pancreatic [36] and prostate [37, 38] cancer 
cells. Studies of capsaicin have reported varying effects, which may be related to non-
TRPV1-mediated responses of capsaicin or differences between the levels of TRPV1 
expression amongst different cancer cell lines. In the LNCaP prostate cancer cell line 
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capsaicin induces cell proliferation via TRPV1 [39], whereas in PC-3 prostate cancer cells 
capsaicin inhibits cell proliferation via a mechanism independent of TRPV1 [40]. 
In these studies we investigated the hypotheses that cell death mediated by pharmacological 
activation of TRPV1 in MCF-7 breast cancer cells is dependent on both the level of TRPV1 
overexpression and the concentration of TRPV1 activator, and that the overexpression of 
TRPV1 and submaximal activation of TRPV1 promotes the proliferation of MCF-7 breast 
cancer cells. We also sought to define the nature of cell death associated with TRPV1 
activation in MCF-7 breast cancer cells. 
2. Methods
2.2 Cell culture 
The MCF-7 Tet-off breast cancer cell line (Clontech) and the MCF-7 parental breast cancer 
cell line (ATCC) were cultured in Dulbecco’s Modified Eagle Medium, (high glucose) 
(DMEM; Invitrogen) supplemented with 10% fetal bovine serum (FBS; Sigma Aldrich), 4 
mM L-glutamine (Invitrogen), and penicillin G (100U/mL)/ streptomycin sulphate (100 
g/mL; Invitrogen) at 37°C with 5% CO2. Cells were supplemented with G418 (100 g/mL; 
Invitrogen), hygromycin B (110 g/mL; Invitrogen) and doxycycline (dox; 1 g/mL; Sigma-
Aldrich) as required. Cells were passaged when the density reached approximately 80%. The 
MCF-7 Tet-off
TRPV1
 cell line was cultured for less than 10 passages prior to experimentation.
2.3 Molecular cloning and development of MCF-7 Tet-off
TRPV1
 cell line
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TRPV1 was amplified from pcDNA3.1 D/V5-His- TOPO-TRPV1 (a generous gift from 
A/Prof C Reilly, University of Utah) [26] using Platinum Pfx DNA polymerase (Invitrogen) 
and the following primers; forward primer 
GCATATATGTCGACACCATGAAGAAATGGA-GCAGCA and reverse primer 
GCATATATGTCGACTCACTTCTCCCCGGAAGCGGC-AGGACTCTT. The TRPV1 
PCR product was ligated into the pGEM-T Easy vector (Promega) then sub-cloned into the 
pBI-G Tet response plasmid (Clontech). The pGEM-TRPV1 and pBI-G-TRPV1 plasmids 
were verified using restriction digest and nucleotide sequencing. The pBI-G-TPRV1 plasmid 
expresses both TRPV1 and β-galactosidase from a bidirectional promoter (Clontech). 
To generate an MCF-7 Tet-Off cell line stably expressing TRPV1, cells were co-transfected 
with the pBI-G-Tet-off-TRPV1 response plasmid and the pTK-Hyg selection plasmid 
(Clontech) using LipofectAMINE 2000 (Invitrogen). Two days after transfection hygromycin 
(110 µg/mL) and dox (1 µg/mL) were added to the culture medium to select for transfected 
cells. Hygromycin resistant colonies were expanded into 24-well plates and screened for dox 
regulated β-galactosidase (β-gal) activity. 
2.4 -Gal assay 
The β-galactosidase Enzyme Assay System (Promega) was used to evaluate dox-regulated β-
gal activity in MCF-7 Tet-Off
TRPV1
 cell lines, since β-gal is an indirect reporter for TRPV1
expression. Briefly, cells were seeded in 96-well plates (8 x 10
3
 cells/well) with vehicle or
dox (1 µg/mL). After 96 h cells were lysed with reporter lysis buffer for 15 min at room 
temperature and then incubated with assay buffer for 30 min at 37°C. Absorbance was 
measured at 415 nm using a Bio-Rad model 550 microplate reader. 
7 
2.5 Real-time RT-PCR 
RNA was isolated from the MCF-7 Tet-Off cells using a Qiagen RNeasy plus mini kit 
(Qiagen). RNA was reverse transcribed using the Omniscript RT kit (Qiagen) and real-time 
RT-PCR was performed using TaqMan Universal PCR Master Mix or Taqman Fast 
Universal Master Mix and TaqMan gene expression assays; TRPV1 (Hs00218912_m1), c-
Fos (Hs00170630_m1), RIP3 (Hs00819388_m1) and 18S rRNA (4319413E). The real-time 
PCR reactions were performed using an ABI PRISM 7500 Sequence Detector or 
StepOnePlus Real-Time PCR System (Applied Biosystems) with the universal cycling 
conditions. The mRNA levels were normalized to 18S rRNA and are presented as fold 
change (2
-∆∆Ct
) relative to control (MCF-7 Tet-Off
TRPV1
 + dox or MCF-7 tet-off). Fold change
levels were calculated using the comparative threshold cycle Ct method [41, 42]. 
2.6 Measurement of intracellular free Ca
2+
 [Ca
2+
]i
MCF-7 Tet-Off
TRPV1
 cells (8 x 10
3
 cells/well) were seeded in 96-well black-walled CellBIND
surface plates (Corning Inc.) and treated with vehicle or various concentrations of dox. 
Measurement of intracellular Ca
2+
 in response to vehicle (ethanol) or various concentrations
of capsaicin was performed at 96 h. Cells were loaded with Fluo-4 AM (4 µM; Invitrogen) 
for 30 min at 37 °C and then incubated for 15 min at room temperature in physical salt 
solution [PSS; 140 mM NaCl, 11.5 mM glucose, 10 mM HEPES, 5.9 mM KaCl, 1.4 mM 
MgCl2, 1.2 mM NaH2PO4, 5 mM NaHCO3, 1.8 mM CaCl2, pH 7.3] at room temperature. 
Fluorescence was measured at 470 – 495 nm excitation and 515 – 575 nm emission using a 
Fluorescence Imaging Plate Reader (FLIPR)
TETRA 
(Molecular Devices). Response over
8 
baseline was assessed as a relative measure of [Ca
2+
]i and peak relative Ca
2+
 was determined
by the maximum relative fluorescence (response over baseline) value achieved during the 800 
s following capsaicin addition. Concentration-response curves and EC50 or IC50 values were 
generated using GraphPad Prism Version 5.01 software (GraphPad Software Inc). The data 
were fitted to a four parameter Hill equation with variable slope. 
2.7 Viable cell number assay 
MCF-7 Tet-Off and MCF-7 Tet-Off
TRPV1
 cells (8 x 10
3
 cells/well) were seeded in 96-well
plates. Cells were treated with vehicle (ethanol) or varying concentrations of capsaicin or dox 
and vehicle . Proliferation was assessd at 24 h, 72 h, 96 h or 120 h by adding CellTiter 
96®Aqueous One Solution Reagent (20 μL) to each well containing 100 μL of culture 
medium and measuring the absorbance at 490 nm using a Bio-Rad model 550 microplate 
Reader. 
2.8 Assessment of cell death 
MCF-7 Tet-Off
TRPV1
 cells (8 x 10
3
 cells/well) were seeded in 96-well black-walled imaging
plates (Becton Dickinson Bioscience) in the presence of dox (0 – 1000 ng/mL). Capsaicin (0 
– 500 µM) or staurosporine (STS, 0 – 3 µM) were added 96 h after seeding and cell death
was assessed at two time points (6 h and 24 h) after capsaicin treatment. For BAPTA 
experiments cells were pre-treated with vehicle or BAPTA (10 mM) for 5 min prior to 
treatment with vehicle, BAPTA (10 mM), capsaicin (3 µM), or BAPTA (10 mM) plus 
capsaicin (3 µM) for 6 h. Cells were stained simultaneously with Hoechst 3342 (10 µg/mL; 
Invitrogen), PI (1 µg/mL; Invitrogen) and YO-PRO-1 (0.2 µM Invitrogen) for 15 min at 37 
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°C. Hoechst stains all cells, YO-PRO-1 can enter cells during apoptosis and PI enters cells 
during the late stages of apoptosis and during necrosis [43, 44]. Images were acquired and 
analyzed using an ImageXpress Micro (Molecular Devices) automated epifluorescent 
microscope with a 10 X objective lens. Images were captured from four fields per well. 
Hoechst 3342 was detected using a DAPI-1160A (Semrock) filter, PI was detected using a 
Cy3-4040B (Semrock) filter and YO-PRO-1 was detected using a GFP-3635B (Semrock) 
filter. Images were analyzed using MetaXpress (V3.1.0.83, Molecular Devices). The Multi-
wavelength Cell Scoring application module was used to calculate the percentage of cells 
positive for each dye. Phase contrast images were captured using a Leica DM IL LED 
inverted microscope, 40 X objective with a Leica DFC 295 camera (Leica). Fluorescent 
images were captured using ImageXpress Micro (Molecular Devices) automated 
epifluorescent microscope with a 10 X objective lens. 
2.9 Statistical analysis 
GraphPad Prism Version 5.01 software (GraphPad Sotfware Inc) was used for the generation, 
95 % confidence interval values and statistical significance were calculated as described in 
the figure legends. 
3. Results
3.1 Generation of an MCF-7 tet-off cell line over-expressing TRPV1 (MCF-7 tet-off
TRPV1
).
A breast cancer cell line model was developed to assess the consequences of overexpression 
of a calcium permeable ion channel in breast cancer cells and the optimal approach and 
conditions to therapeutically target such channels. The MCF-7 cell line was selected because 
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MCF-7 cells have low levels of TRPV1, a calcium permeable ion channel with well 
characterized pharmacological modulators (e.g. capsaicin). The TRPV1 over expressing 
MCF-7 cell line was generated using a plasmid with a bi-directional promoter that expressed 
both TRPV1 and -gal in the absence of dox. More than 50 stables lines were generated; 
three showed clear dox-sensitive -gal expression with TRPV1 mRNA level increases and 
TRPV1 calcium responses to the TRPV1 activator capsaicin as a measure of functional 
TRPV1 protein expression, as described for the selected cell line below and in supplementary 
data. To validate the stable cell lines -gal activity was assessed as a marker of TRPV1 
expression. Removal of dox increased -gal activity in the cells indicating TRPV1 expression 
(Fig. 1A and Fig. S2A). Real-time RT-PCR confirmed that TRPV1 mRNA was elevated in 
the absence of dox (Fig. 1B and Fig. S1 and S2B), and finally to assess the activity of 
TRPV1, stably expressing cells were stimulated with the TRPV1 agonist capsaicin and 
increases in [Ca
2+
]i measured. Induction of TRPV1 expression (absence of dox) was
associated with a sustained increase in [Ca
2+
]i with the addition of capsaicin (Fig. 1C and Fig.
S2C and D). One of the stable cell lines was selected for further detailed assessment and is 
referred to as MCF-7 tet-off
TRPV1
. These initial studies show that MCF-7 tet-off
TRPV1
represents a breast cancer cell line with inducible expression of functional TRPV1. 
3.2 Assessment of TRPV1-mediated increases in [Ca
2+
]i in MCF-7 tet-off
TRPV1
 cells.
MCF-7 tet-off
TRPV1
 cells were treated with increasing concentrations of dox, to concentration-
dependently decrease the levels of TRPV1 and the consequences of capsaicin (3 M) –
mediated increases in [Ca
2+
]i were assessed. As expected, capsaicin-mediated increases in
[Ca
2+
]i decreased with decreasing TRPV1 expression levels, with a dox IC50 of 0.117 ng/mL
(Fig. 2A). The maximal capsaicin-mediated increase in [Ca
2+
]i was reduced at dox
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concentrations greater than 0.03 ng/mL, sub-maximal increases in [Ca
2+
]i were observed with 
0.1 and 0.3 ng/mL dox. Concentrations of dox greater than 1 ng/mL were sufficient to almost 
abolish capsaicin-mediated increases in [Ca
2+
]i (Fig. 2A). Similar results were seen with the 
other two stable clones (Fig. S3A and B). 
 
MCF-7 tet-off
TRPV1
 cells were then treated with increasing concentrations of capsaicin in the 
presence or absence of dox. When TRPV1 over-expression was not induced (+ dox 1 g/mL) 
a slight increase in [Ca
2+
]i was observed at high concentrations of capsaicin with an EC50 of 
705 nM (Fig. 2B) and similar values observed for the other two clones (Fig. S3C and D). The 
calcium response in the presence of dox may be caused by endogenous TRPV1 in the MCF-7 
cells and/or modest “leaky” expression of TRPV1 from the pBI-G-TRPV1 plasmid (Fig. S1) 
and/or non-specific effects of capsaicin. However, when TRPV1 was over-expressed (- dox) 
a significant concentration-dependent increase in [Ca
2+
]i was observed with increasing 
concentrations of capsaicin, with an EC50 of 175 nM (Fig. 2B). Similar values were observed 
for the other two clones (Fig S3C and D). 
 
3.3 Assessment of the effects of TRPV1 activation on cell viability and dependence on TRPV1 
expression levels.  
 
The effect of capsaicin on viable cell number was assessed using an MTS assay in the MCF-7 
tet-off
TRPV1
 (Fig. 3A and B) and MCF-7 tet-off parental cell lines (Fig. 3C and D) cultured 
with varying concentrations of capsaicin. Similar studies were conducted in the two other 
clonal cell lines with the results shown in supplementary figures (Fig. S4A, B, C and D). In 
the absence of TRPV1 overexpression, capsaicin had no effect on viable cell numbers of 
MCF-7 tet-off
TRPV1
 (+ dox) or parental MCF-7 tet-off cells after 24 h (Fig. 3A and C). After 
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96 h only the highest concentration of capsaicin (0.3 mM) affected MCF-7 cells without 
TRPV1 overexpression (Fig. 3B and D). In the presence of TRPV1 over-expression (- dox), 
increasing concentrations of capsaicin reduced viable cell numbers in a concentration-
dependent manner at both 24 h (Fig. 3A) and 96 h (Fig. 3B) with EC50 values of 713 nM and 
898 nM, respectively. Vercelli showed contrasting findings, inhibition of MCF-7 cell 
viability with capsaicin treatment [45], however 0.1 nM and 100 µM capsaicin had the same 
ability to inhibit cell viability, which is not consistent with the results of other studies [26]. 
Furthermore, the role of TRPV1 in the effect of capsaicin on MCF-7 cells was not 
conclusively demonstrated [45]. 
The level of TRPV1 over-expression required to affect MCF-7 viable cell numbers in the 
presence of capsaicin was then tested. The concentration response curve showed that TRPV1 
over-expression clearly sensitized MCF-7 cells to the effects of 3 μM capsaicin (EC50 = 0.119 
ng/mL dox) (Fig. 4, and Fig. S5A and B). 
3.4 Overexpression or activation of TRPV1 does not promote proliferation of MCF-7 cells. 
MCF-7 cell proliferation was assessed with increasing levels of TRPV1 over-expression 
without the addition of capsaicin. The growth curves show that the over-expression of 
TRPV1 had no effect on MCF-7 proliferation (Fig. 5A). 
Activation of TRPV1 could promote proliferation if the nature of the [Ca
2+
]i signal was
appropriate for proliferative signaling. Such activation of proliferation could limit the use of 
ion channel activation in cancer therapy. However, at no levels of TRPV1 expression did 
capsaicin produce an increase in cell numbers at 48 h (Fig. 5B) or 96 h (Fig. 5C). Instead, 
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consistent with the results presented above, high levels of TRPV1 over-expression (e.g. 0 
ng/mL and 0.1 ng/mL dox) with sub-maximal capsaicin (3 M) reduced the number of viable 
MCF-7 tet-off
TRPV1
 cells (Fig. 5B and C).
3.5 Activation of TRPV1 induces cell death in MCF-7 cells that over-express TRPV1 
To further assess the capsaicin-mediated reduction in cell number in TRPV1 overexpressing 
MCF-7 tet-off
TRPV1
 cells, a cell death assay was performed using three fluorescent dyes,
which distinguish between live (Hoechst 3342 only positive), apoptotic (YO-PRO-1 and 
Hoechst 3342 positive, and PI negative) and necrotic (YO-PRO-1, PI and Hoechst 3342 
positive) cell populations. MCF-7 tet-off
TRPV1
 cells were treated with varying concentrations
of staurosporine (STS) or capsaicin in the absence of dox (TRPV1 over-expressed). 
staurosporin induces apoptosis in various cell types including MCF-7 cells [46, 47]. Phase 
contrast images show characteristic necrotic morphology for the capsaicin treated cells, 
compared to the apoptotic morphology observed in the staurosporin treated cells (Fig. 6A) 
[48]. The fluorescent images show that the capsaicin treated cells are mostly positive for YO-
PRO-1 and PI, and only a few cells were positive for YO-PRO-1 but not PI, indicating 
necrosis (Fig 6A), whereas many of the staurosporin treated cells were positive for YO-PRO-
1 but not PI, indicating early apoptosis (Fig 6A). Quantification of the staining showed that 
capsaicin (0.3 – 3.0 M) and staurosporin (0.1 - 3.0 M) both induced cell death in MCF-7 
tet-off
TRPV1
 cells overexpressing TRPV1 (Fig. 6B). However, staurosporin (3 M) was
associated with 8% of cells being YO-PRO-1 positive and PI negative populations indicating 
apoptosis, but only 1% of cells were in this population with capsaicin (3 M) (Fig. 6C) at 6 h. 
Hence, capsaicin-induced cell death observed in cells over-expressing TRPV1 occurs via a 
mechanism primarily mediated by a necrotic pathway. 
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Since capsaicin activated TRPV1 is also permeable to Na
+
 and Mg
2+
 [49], the dependence of 
capsaicin-mediated cell death on Ca
2+
 influx was assessed. The addition of the Ca
2+
 chelator 
BAPTA protected MCF-7 cells against capsaicin-induced cell death, demonstrating that the 
cell death effect of capsaicin is indeed calcium-dependent (Fig. S6).  
 
 
3.6 Capsaicin induced cell death in MCF-7 cells is concentration dependent and contingent 
upon the level of TRPV1. 
 
The effect of TRPV1 expression levels and capsaicin concentration on cell death was 
assessed in MCF-7 tet-off
TRPV1
 cells. Figures 7A & B show 3-dimensional graphs of how 
capsaicin and dox concentrations affected the percentage of dead cells (YO-PRO and PI 
staining). Consistent with a rapid necrotic cell death mechanism, similar results were 
observed at both 6 h (Fig. 7A) and 24 h (Fig. 7B) of capsaicin exposure. The highest 
percentage of cell death (~80%) was observed with the highest TRPV1 expression level (0 
ng/mL dox) and the highest concentrations of capsaicin (3 M and 500 M) (Fig. 7). 
Expression levels of TRPV1 that induced sub-maximal [Ca
2+
]i increases (0.1 and 0.3 ng/mL 
dox) also resulted in a sub-maximal percentage of cell death (15-56%) when treated with 
capsaicin at 3 M or 500 M. As the expression level of TRPV1 increased, the concentration 
of capsaicin required to induce cell death decreased; for example with the highest level of 
TRPV1 expression (0 ng/mL dox) 0.3 M capsaicin induced cell death, while at a lower level 
of TRPV1 (0.3 ng/mL dox) 3 M capsaicin was required to induce cell death (Fig. 7). This 
suggests that the level of TRPV1 expression is a critical determinant of the capsaicin 
concentration required to induce cell death in breast cancer cells. 
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3.7 Activation of TRPV1 induced c-Fos and RIP3 expression 
To further define the consequences of TRPV1 activation in MCF-7 breast cancer cells, the 
effect of activating overexpressed TRPV1 with capsaicin on c-Fos, a component of the early 
response transcription factor, AP-1 [50], was assessed in MCF-7 tet-off
TRPV1
 cells. In the
absence of TRPV1 overexpression (+ dox) capsaicin had no effect on c-Fos mRNA levels 
(Fig. 8A). However, when TRPV1 expression was induced, c-Fos expression was elevated by 
capsaicin as early as 0.5 h, with highest levels observed at 3 h (Fig. 8A). To further verify the 
induction of necrosis by capsaicin treatment in TRPV1 overexpressing MCF-7 cells the 
expression of a necrotic marker, RIP3 [51, 52] was assessed. At 12 h after capsaicin treatment 
the expression of RIP3 was elevated almost 2-fold in the presence compared to the absence of 
TRPV1 over-expression (Fig 8B). 
4. Discussion
The identification of ion channels with increased expression in some cancer cell lines and 
clinical samples, has led to the hypothesis that pharmacological modulators of these ion 
channels may represent potential therapies for specific cancers. Inhibition of ion channels has 
been the first focus for potential therapies with studies looking at the effectiveness of 
silencing specific ion channels or using pharmacological inhibitors to attenuate processes 
important in cancer progression such as proliferation, migration and invasion and to examine 
the importance of the calcium signal in cell cycle progression and motility. However, 
activation of ion channels to produce sustained high levels of [Ca
2+
]i and subsequent cell
death has also been proposed as a strategy and is supported by the constitutively active TRPL 
16 
[25] and the non-selective TRPM8 activator menthol [53] producing cell death in LNCaP 
prostate cancer cells that overexpress the Ca2+ permeable ion channels TRPL [25] or TRPM8
[17], respectively. 
Targeting overexpressed ion channels through pharmacological activation could potentially 
potentiate cellular proliferation at low concentrations in cancer cells that do not overexpress 
the calcium channel sufficiently such that activation produces cell death [28, 39]. Our studies 
using tet-regulated TRPV1 expression in MCF-7 breast cancer cells, indicated that both 
capsaicin-mediated [Ca
2+
]i responses and cell death are dependent on the concentration of
capsaicin and the level of TRPV1. However, at no level of TRPV1 expression or capsaicin 
concentration was a promotion of cellular proliferation observed. Capsaicin concentrations 
that did not produce cell death but were associated with increases in [Ca
2+
]i did not increase
cellular proliferation. The lack of an increase in MCF-7 cell number produced by any 
concentration of capsaicin at any level of TRPV1 expression including those associated with 
increases in [Ca
2+
]i may seem surprising given the important role of Ca
2+
 in cell cycle
progression. However the nature of the change in [Ca
2+
]i (e.g. spatial location and temporal
changes) is a critical regulator of many Ca
2+
-dependent processes including gene
transcription and cell cycle progression [54-56]. Thus pharmacological activators against 
overexpressed Ca
2+
 permeable ion channels may not suffer from the clinical disadvantage of
promotion of cellular proliferation in tumors with lower levels of ion channel overexpression. 
Although TRPV1 dependent, the EC50 for cell death for capsaicin was higher than for peak 
[Ca
2+
]i. This indicates that the level of ion channel overexpression is likely to be a critical
determinant of the therapeutic effectiveness of a calcium permeable ion channel activator in 
cancer therapy. The assessment of the degree of ion channel overexpression will therefore be 
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important in identifying patient groups for such therapies. Although capsaicin mediated cell 
death is reported in some cancer cell lines, in many cases the concentrations used were well 
above those used in this study and could be due to the non TRPV1-mechanisms that have 
been reported at high concentrations of capsaicin [26, 40].  
 
The identification of other calcium permeable ion channels with pronounced overexpression 
in clinical breast cancers and cell lines and the assessment of the consequences of their 
activation in vitro and in vivo are now required. The study of such ion channels in breast 
cancer cells should also assess the consequences of gene silencing and pharmacological 
inhibition. Given the reported elevated levels of TRPV6 in basal-like breast cancers [10] and 
the recent identification of an inhibitor of TRPV6 [57], it will be particularly interesting to 
determine if activation of TRPV6 could promote cell death in basal-in like breast cancers in 
vitro and in vivo.  
 
High content analysis of PI and YO-PRO-1 permeability and differences with staurosporin 
effects and the rapid nature of cell death (6 h) is consistent with a rapid loss of the 
maintenance of critical ion gradients, the loss of plasma membrane integrity and induction of 
necrosis. Furthermore, the morphology of the capsaicin treated cells compared to the 
staurosporin treated cells and the elevated RIP3 expression in capsaicin treated cells with 
TRPV1 over-expression, indicate induction of necrotic cell death [48, 51]. Necrotic cell death 
can be induced by increased intracellular calcium [59], consistent with our findings. Necrosis 
is traditionally considered uncontrolled cell death, however, programmed necrosis has been 
suggested [60-62]. Necrosis can be induced in cancer cells by DNA alkylating agents, 
irradiation and by photodynamic treatment [63-65]. Indeed, in breast cancer patients 
anthracyclin predominately induces necrotic cell death [66]. Photodynamic treatment induces 
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cell death in an apoptotic-resistant breast cancer cell line [64], suggesting that treatments that 
induce necrotic cell death may be effective for tumors with defective apoptotic pathways [62, 
67]. 
 
The early response gene, c-Fos was initially considered as a promoter of proliferation and a 
proto-oncogene, however, more recent studies show that c-Fos also has a role in cell death 
[68, 69]. The c-Fos protein forms part of the AP-1 transcription factor and the effect of c-Fos 
on cell proliferation or cell death depends on various factors, including the subunits that 
comprise AP-1 and the type of stimuli [68, 69]. Regulation of c-Fos by MEKs and ERKs and 
the downstream targets of AP-1 are either be pro-proliferative (cyclin D1 and CDK) or pro-
apoptotic (p52 and p21). Since rapid increases in [Ca
2+
]i are a well-established inducer of c-
Fos expression [70, 71], c-Fos expression was assessed in MCF-7 tet-off
TRPV1
 cells. The 
highest c-Fos expression was observed at 3 h after TRPV1 activation with capsaicin and this 
expression decreased at 6 h, when cell death was observed, indicating c-Fos expression is a 
precursor to cell death. A rapid induction of c-Fos expression has previously been observed 
in preneoplastic cell lines and lymphoid cells after growth factor deprivation-mediated cell 
death [72, 73]. Elevated c-Fos expression is a feature of the early stages of mammary gland 
involution [74] and tamoxifen induced cell death in SK-BR-3 breast cancer cells [75]. This 
suggests that the elevations in c-Fos that were observed 3 h after capsaicin treatment, may be 
an early indicator of cell death mediated by capsaicin in breast cancer cells that overexpress 
TRPV1.  
 
This model of calcium permeable ion channel overexpression in breast cancer cells provides 
evidence that the targeting of calcium permeable ion channels with activators may represent 
an opportunity to induce death of breast cancer cells without promotion of cellular 
19 
proliferation. Further studies are required to determine whether such activation may also 
promote sensitivity to cell death inducers, such as seen for silencing of specific calcium 
efflux pump isoforms [22]. These studies also suggest that activating calcium permeable ion 
channels may be an effective tool to mediate breast cancer cell death, in a way that may 
bypass some resistance mechanisms. However, as yet no ion channel with sufficiently high 
endogenous levels has yet been characterised in a breast cancer cell line and the 
consequences of sustained ion channel activation warrants further study. The expansion of 
available pharmacological activators of ion channels and the identification of other Ca
2+
channel overexpressed in specific cancers may allow the eventual development of oncology 
agents that act via this mechanism. 
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Figure Legends 
 
Fig. 1. Characterization of MCF-7 Tet-off cells stably expressing TRPV1. Cells were treated 
with vehicle or dox (1 g/mL) for 96 h. (A) -Gal activity in MCF-7 Tet-offTRPV1 cells. The 
data are mean ± SD (n = 3). (B) Relative TRPV1 mRNA levels in MCF-7 Tet-off
TRPV1
 cells. 
The data are normalized to 18S RNA and expressed as mean ±SD (n = 3) relative to + dox. 
(C) Relative [Ca
2+
]i response to capsaicin (10 M) in MCF-7 Tet-off
TRPV1
 cells in the 
presence or absence of dox. Relative [Ca
2+
]i (black lines) ± SD (grey lines) (n = 3).  
 
Fig. 2. Effect of TRPV1 expression and activity levels on capsaicin-mediated increases in 
[Ca
2+
]i. (A) Assessment of peak relative [Ca
2+
]i in MCF-7 Tet-off
TRPV1
 cells treated with 
various concentrations of dox (96 h) prior to stimulation with capsaicin (3 M). (B) 
Assessment of peak relative [Ca
2+
]i in MCF-7 Tet-off
TRPV1
 cells treated with dox (1 g/mL; 
96 h) prior to stimulation with various concentrations of capsaicin. Graphs represent the mean 
concentration-response curves of peak relative [Ca
2+
]i ± SD (n = 9) from three independent 
assays; * denotes p < 0.05 using two-way ANOVA with Bonferroni post-hoc test. 
 
Fig. 3. The TRPV1 activator capsaicin reduces the number of viable MCF-7 cells over-
expressing TRPV1. (A-D) MCF-7 Tet-off
TRPV1
 cells (A and B) or MCF-7 tet-off cells (C and 
D) were treated with vehicle or dox (1 g/mL) for 96 h prior to treatment with various 
concentrations of capsaicin for 24 h (A and C) or 96 h (B and D). Viable cell numbers were 
assessed using an MTS assay. Graphs represent the mean concentration-response curves of 
absorbance ± SD (n = 9) from three independent assays; * denotes p < 0.05 using two-way 
ANOVA with Bonferroni post-hoc test. 
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Fig. 4. TRPV1 expression levels effect capsaicin-meditated effects on MCF-7 cell viability. 
MCF-7 Tet-off
TRPV1
 cells were treated with vehicle or dox (1 g/mL) for 96 h prior to 
treatment with capsaicin (3 M; 24 h). Viable cell numbers were assessed using an MTS 
assay. Graph represents the mean concentration-response curves of absorbance ± SD (n = 9) 
from three independent assays; * denotes p < 0.05 using one-way ANOVA with Dunnett 
post-hoc test. 
 
Fig. 5. TRPV1 over-expression or activation does not promote MCF-7 cell proliferation. (A) 
MTS assay of MCF-7 tet-off
 TRPV1
 cells treated with vehicle or various concentrations of dox 
for 24 h, 72 h or 120 h. The data are mean ± SD (n = 15) from five independent assays. (B 
and C) MTS assay of MCF-7 tet-off
 TRPV1
 cells treated with vehicle or various concentrations 
of dox for 24 h prior to treatment with capsaicin (3 M) for 48 h (B) or 96 h (C). The data are 
mean ± SD (n = 15) from five independent assays; * denotes p < 0.05 compared to vehicle at 
each dox concentration using two-way ANOVA with Bonferroni post-hoc test. 
 
Fig. 6. TRPV1 activation induces cell death in MCF-7 cells over-expressing TRPV1. (A,B 
and C) MCF-7 Tet-off
TRPV1
 cells were cultured in the absence of dox for 96 h prior to 
treatment with various concentrations of staurosporine (STS) or capsaicin for 6 h. Phase 
contrast images (A, top panel). Cells were stained with Hoechst 3342 (blue), Yo-Pro-1 
(green) and PI (red) (A, bottom panel). Cells stained with both YO-PRO-1 and PI (purple) 
indicate a necrotic population (A and B) and cells stained for YO-PRO-1 only indicate an 
apoptotic population (A and C). Images are representative of 3 independent experiments and 
the data are mean ± SD (n = 3). 
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Fig. 7. Cell death is dependent on the level of TRPV1 expression and activation. (A and B) 
MCF-7 Tet-off
TRPV1
 cells were treated with various concentrations of dox for 96 h prior to 
treatment with various concentrations of capsaicin for 6 h (A) or 24 h (B). Data are presented 
as percentage YO-PRO-1 and PI positivity and are representative of 3 independent 
experiments. 
 
Fig. 8. Effect of TRPV1 activation and over-expression on c-Fos and RIP3 expression in 
MCF-7 cells. MCF-7 Tet-off
TRPV1
 cells were cultured in the presence or absence of dox (1 
g/mL) for 96 h prior to treatment with capsaicin (3 μM) for various time points. Relative c-
Fos (A) or RIP3 (B) mRNA expression. Data are presented as fold change and are 
representative of three independent assays performed in duplicate. The data are mean ± SD (n 
= 3) * denotes p < 0.05 compared using two-way ANOVA with Bonferroni post-hoc test (A) 
or t-test (B). 
 
 
Supplementary Figure Legends 
Fig. S1. Characterization of TRPV1 expression in MCF-7 tet-off cells. Cells were treated 
with vehicle or dox (1 g/mL) for 96 h. Relative TRPV1 mRNA in 1) MCF-7 tet-off, 2) 
MCF-7 tet-off PPARalpha, 3) MCF-7 tet-off
TRPV1
 clone 30 +Dox and 4) MCF-7 tet-off
TRPV1
 
clone 30 –Dox. The data are normalized to 18S RNA and expressed as mean ±SD (n = 3 
technical replicates) relative to MCF-7 cells. 
Fig. S2. Characterization of MCF-7 Tet-off clones 4 and 35 stably expressing TRPV1. Cells 
were treated with vehicle or dox (1 g/mL) for 96 h. (A) -Gal activity in MCF-7 Tet-
off
TRPV1
 cells. The data are mean ± SD (n = 3). (B) Relative TRPV1 mRNA levels in MCF-7 
Tet-off
TRPV1
 cells. The data are normalized to 18S RNA and expressed as mean ±SD (n = 3) 
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relative to + dox. (C) Relative [Ca
2+
]i response to capsaicin (10 M) in MCF-7 Tet-off
TRPV1
 
cells in the presence or absence of dox. Relative [Ca
2+
]i (black lines) ± SD (grey lines) (n = 
3).  
 
Fig. S3. Effect of TRPV1 expression and activity levels on capsaicin-mediated increases in 
[Ca
2+
]I in MCF-7 Tet-off
TRPV1
 clones 4 and 35. (A) Assessment of peak relative [Ca
2+
]i in 
MCF-7 Tet-off
TRPV1
 cells treated with various concentrations of dox (96 h) prior to 
stimulation with capsaicin (3 M). (B) Assessment of peak relative [Ca2+]i in MCF-7 Tet-
off
TRPV1
 cells treated with dox (1 g/mL; 96 h) prior to stimulation with various 
concentrations of capsaicin. Graphs represent the mean concentration-response curves of 
peak relative [Ca
2+
]i ± SD (n = 9) from three independent assays; * denotes p < 0.05 using 
two-way ANOVA with Bonferroni post-hoc test. 
 
Fig. S4. Effect of TRPV1 activator capsaicin on the number of viable MCF-7 Tet-off
TRPV1
 
clones 4 and 35. (A-D) MCF-7 Tet-off
TRPV1
 clone 4 cells (A and B) or MCF-7 Tet-off
 TRPV1
 
clone 35 cells (C and D) were treated with vehicle or dox (1 g/mL) for 96 h prior to 
treatment with various concentrations of capsaicin for 24 h (A and C) or 96 h (B and D). 
Viable cell numbers were assessed using an MTS assay. Graphs represent the mean 
concentration-response curves of absorbance ± SD (n = 9) from three independent assays; * 
denotes p < 0.05 using two-way ANOVA with Bonferroni post-hoc test. 
 
Fig. S5. TRPV1 expression levels effect capsaicin-meditated effects on viability of MCF-7 
Tet-off
TRPV1
 clones 4 and 35. MCF-7 Tet-off
TRPV1
 cells were treated with vehicle or dox (1 
g/mL) for 96 h prior to treatment with capsaicin (3 M; 24 h). Viable cell numbers were 
assessed using an MTS assay. Graph represents the mean concentration-response curves of 
33 
 
absorbance ± SD (n = 9) from three independent assays; * denotes p < 0.05 using one-way 
ANOVA with Dunnett post-hoc test. 
 
Fig. S6. The cell death induced in MCF-7 cells with TRPV1 over-expression when TRPV1 is 
activated involves Ca
2+
. MCF-7 Tet-off
TRPV1
 cells were cultured in the absence of dox for 96 
h prior to the addition of capsaicin (or vehicle)  ± BAPTA for 6 h. Cells stained with both 
YO-PRO-1 and PI indicate a necrotic population. Data are mean ± SD (n = 3) from 3 
independent assays. 
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